To include your compound in the COVID-19 Resource Center, submit it here.

ADL5945: Phase II data

Top-line data from the double-blind, U.S. Phase II Study 242 trial in 131 chronic non-cancer pain patients with OIC showed that twice-daily 0.25 mg ADL5945

Read the full 251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE